A sublingual formulation of cladribine, which is the active ingredient of the approved oral treatment Mavenclad, in relapsing multiple sclerosis (MS), showed comparable pharmacological properties ...
However, this route is associated with several drawbacks. Sublingual delivery could be a more patient friendly alternative: it is easy, fast, reliable and may even reduce a number of side effects. In ...